Hao, Yan. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 98-115). / Abstracts in English and Chinese. / Acknowledgement --- p.i / Abstract --- p.iii / 摘要 --- p.v / List of Abbreviations --- p.vii / List of Figures --- p.x / List of Tables --- p.xi / List of Primers --- p.xii / Publications arising from this study --- p.xiii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Alzheimer's disease --- p.1 / Chapter 1.2 --- APP and its functions --- p.4 / Chapter 1.2.1 --- APP processing --- p.7 / Chapter 1.3 --- APPc-interacting proteins --- p.10 / Chapter 1.3.1 --- FE65 --- p.10 / Chapter 1.3.2 --- Xllα and Xl1β --- p.12 / Chapter 1.3.3 --- JIP-1 --- p.13 / Chapter 1.3.4 --- Dabl and Dab2 --- p.15 / Chapter 1.3.5 --- SNX17 --- p.15 / Chapter 1.3.6 --- Numb --- p.15 / Chapter 1.3.7 --- AIDA-1 --- p.16 / Chapter 1.4 --- Objectives of the project --- p.18 / Chapter 1.4.1 --- Engulfment adaptor protein 1 (GULP1) --- p.19 / Chapter 1.4.2 --- Specific aims of my study --- p.20 / Chapter Chapter 2 --- General Methodology --- p.22 / Chapter 2.1 --- Bacterial culture --- p.22 / Chapter 2.2 --- Mini-preparation/Midi-preparation of plasmid DNA --- p.22 / Chapter 2.3 --- Spectrophotometric analysis of DNA --- p.22 / Chapter 2.4 --- Agarose gel electrophoresis for DNA --- p.23 / Chapter 2.5 --- Preparation of competent E. coli --- p.23 / Chapter 2.6 --- Transformation of competent E. coli --- p.24 / Chapter 2.7 --- Molecular cloning --- p.24 / Chapter 2.7.1 --- Preparation of the cloning vector and insert --- p.25 / Chapter 2.7.2 --- Isolation of DNA from agarose gel --- p.25 / Chapter 2.7.3 --- DNA ligation and transformation --- p.25 / Chapter 2.7.4 --- Rapid screening for ligated plasmid --- p.26 / Chapter 2.8 --- Site-directed mutagenesis --- p.26 / Chapter 2.9 --- Cell culture and transfection --- p.27 / Chapter 2.10 --- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) --- p.28 / Chapter 2.11 --- Western blotting --- p.29 / Chapter Chapter 3 --- Investigation of the GULP1-APP interaction and the effect of GULP1 on APP processing --- p.31 / Chapter 3.1 --- Introduction --- p.31 / Chapter 3.2 --- Materials and methods --- p.34 / Chapter 3.2.1 --- DNA constructs --- p.34 / Chapter 3.2.2 --- Antibodies --- p.34 / Chapter 3.2.3 --- GST pull-down assays --- p.35 / Chapter 3.2.4 --- Rat tissues preparation --- p.36 / Chapter 3.2.5 --- Immunostaining --- p.36 / Chapter 3.2.6 --- "siRNA knockdown of GULPl in CHO, HEK293 and SHSY5Y cells" --- p.37 / Chapter 3.2.7 --- Luciferase assays --- p.37 / Chapter 3.2.9 --- Tricine-SDS/PAGE analysis for APP CTFs --- p.38 / Chapter 3.2.9 --- Aβ enzyme-linked immunosorbent assay (ELISA) --- p.39 / Chapter 3.2.10 --- Statistical analysis --- p.40 / Chapter 3.3 --- Results --- p.40 / Chapter 3.3.1 --- GULP1 F145V mutant abandons the GULP1-APP interaction --- p.40 / Chapter 3.3.2 --- GULP1 and APP colocalize in neurons --- p.45 / Chapter 3.3.3 --- "siRNA mediated knockdown of GULPl in CHO, HEK293 and SHSY5Y cells" --- p.48 / Chapter 3.3.4 --- GULP1 enhances the cleavage of APP in APP-GAL4 cleavage system --- p.49 / Chapter 3.3.5 --- GULP1 alters APP processing by increasing the secretion of APP CTFs --- p.52 / Chapter 3.3.6 --- GULP1 stimulates Aβ secretion --- p.55 / Chapter 3.4 --- Discussion --- p.57 / Chapter Chapter 4 --- Identification and characterization of GULPl phosphorylation sites --- p.60 / Chapter 4.1 --- Introduction --- p.60 / Chapter 4.2 --- Materials and Methods --- p.60 / Chapter 4.2.1 --- DNA constructs --- p.61 / Chapter 4.2.2 --- Antibodies --- p.61 / Chapter 4.2.3 --- Expression and purification of GST fusion proteins --- p.61 / Chapter 4.2.4 --- In vitro phosphorylation of GULP1 by cdk5/p35 --- p.62 / Chapter 4.3 --- Results --- p.62 / Chapter 4.3.1 --- GULP1 Ser223 can be phosphorylated by cdk5/p35 in vivo --- p.62 / Chapter 4.3.2 --- The phosphorylation ofGULPl Thr35 completely abolished the GULP1-APP interaction --- p.67 / Chapter 4.4 --- Discussion --- p.70 / Chapter Chapter 5 --- Crystallization of the PTB domains of GULPl and GULP1t35d…… --- p.72 / Chapter 5.1 --- Introduction --- p.72 / Chapter 5.2 --- Materials and Methods --- p.72 / Chapter 5.2.1 --- DNA constructs --- p.72 / Chapter 5.2.2 --- Small-scale protein expression and purification --- p.73 / Chapter 5.2.3 --- Large-scale protein expression and purification --- p.73 / Chapter 5.2.4 --- Dynamic light scattering measurement --- p.76 / Chapter 5.2.5 --- Crystallization screening GULP1-PTB --- p.76 / Chapter 5.2.6 --- Optimization of GULP1-PTB crystals by grid screen --- p.76 / Chapter 5.2.7 --- Optimization of GULPl -PTB crystals by additive screen and detergent screen --- p.79 / Chapter 5.3 --- Results --- p.79 / Chapter 5.3.1 --- Large-scale expression and purification of GULP 1-PTB --- p.79 / Chapter 5.3.2 --- Small-scale expression and purification of GULP1T35d-PTB --- p.86 / Chapter 5.3.3 --- Crystallization screening and optimization --- p.88 / Chapter 5.4 --- Discussion --- p.91 / Chapter Chapter 6 --- Conclusion and future perspective --- p.94 / Chapter 6.1 --- Conclusion --- p.94 / Chapter 6.2 --- Future perspective --- p.95 / References --- p.98

No description available.

No description available.

Protein (mis)folding into highly ordered, fibrillar structures, amyloid fibrils, is a hallmark of several, mainly neurodegenerative, disorders. The mechanism of this supra-molecular self-assembly reaction, as well as its relationship to protein folding are not well understood. In particular, the molecular origin of the metastability of the soluble state of proteins with respect to the aggregated states has not been clearly established. In this dissertation, it is demonstrated, that highly accurate kinetic experiments, using a novel biosensing method, can yield fundamental insight into the dynamics of proteins in the region of the free energy landscape corresponding to protein aggregation. First, a section on Method development describes the extension and elaboration of the previously established kinetic assay relying on quartz crystal microbalance measurements for the study of amyloid fibril elongation (Chapter 3). This methodology is then applied in order to study in great detail the origin of the various contributions to the free energy barriers separating the soluble state of a protein from its aggregated state. In particular, the relative importance of residual structure, hydrophobicity (Chapter 4) and electrostatic interactions (Chapter 5) for the total free energy of activation are discussed. In the last part of this thesis (Chapter 6), it is demonstrated that this biosensing method can also be used to study the binding of small molecules to amyloid fibrils, a very useful feature in the framework of the quest for potential inhibitors of amyloid formation. In addition, it is shown that Thioflavin T, to-date the most frequently employed fluorescent label molecule for bulk solution kinetic studies, can in the presence of potential amyloid inhibitor candidates be highly unreliable as a means to quantify the effect of the inhibitor on amyloid formation kinetics. In summary, the work in this thesis contributes to both the fundamental and the applied aspects of the field of protein aggregation.

Obesidade na idade adulta é um fator de risco para o desenvolvimento de demência. O aumento da prevalência de obesidade, assim como o aumento da expectativa de vida na população tornam mais importante avaliar estratégias de prevenção e tratamento que possam diminuir o risco de declínio cognitivo. Neste estudo, foi avaliado se, em idosos obesos com Comprometimento Cognitivo Leve, a perda de peso induzida por dieta poderia melhorar aspectos da cognição, e se o genótipo para apoliproteína E, perfil metabólico e marcadores inflamatórios também teriam influência. Foi realizado um ensaio clínico prospectivo, randomizado de 1:1, de 12 meses, no Ambulatório de Endocrinologia do Hospital das Clínicas da Faculdade de Medicina da USP, entre 2011 e 2013, incluindo pacientes com 60 anos ou mais, com índice de massa corporal maior ou igual a 30 kg/m2, com Comprometimento cognitivo leve. Eles foram randomizados em dois grupos, um com assistência médica convencional (grupo convencional), outro adicionalmente com reuniões de orientação alimentar (26 a 28 sessões em 12 meses), com objetivo de obter maior perda de peso (grupo intensivo). Dos 1605 voluntários foram selecionados 80 pacientes, com idade média de 68,1 ±4,9 anos, escolaridade de 8,8 ±4,6 anos, IMC 35,5±4,4kg/m2; 13 (16,3%) eram do sexo masculino, 67 (83,6%) apresentavam síndrome metabólica; 50 (62,5%) eram fisicamente ativos. Os grupos eram semelhantes quanto às características iniciais. Após 12 meses, houve diminuição média de IMC de 1,7±1,8kg/m2 (4,9% do peso), e 85% da perda de peso foi em gordura corporal; sendo a variação semelhante entre os grupos. Para a maioria dos testes cognitivos aplicados houve melhora, sem diferença estatisticamente significativa entre os grupos. Na análise do grupo todo, a perda de peso induzida por dieta foi associada a melhora em avaliação de memória, função executiva, atenção e queixas subjetivas, tendo sido essa associação mais forte abaixo dos 70 anos e em carreadores do alelo 4 da apoliproteína E. Variação de insulinemia, HOMA-IR, triglicérides, proteína C reativa e leptina estiveram associadas à melhora em alguns testes cognitivos; risco maior de piora foi associado a níveis mais altos de pressão arterial (memória e cognição global) e de hemoglobina glicada (executivo/visuo-espacial) e de IL6 (atenção e velocidade de processamento); adiponectina mais alta diminuiu risco de piora (memória visual/verbal). Houve melhora principalmente em memória verbal, visual e memória de trabalho associadas à dieta, com relação à diminuição de consumo calórico, de carboidratos e gorduras, e sem relação com diminuição de consumo proteico. Houve melhora na avaliação funcional em relação à velocidade de marcha e força de membros inferiores e melhora na qualidade de vida associada à capacidade funcional, mostrando que a intervenção não trouxe prejuízo a essas áreas. A intervenção com restrição calórica em idosos obesos, com objetivo de promover perda de peso, foi benéfica em diversos aspectos da cognição e segura do ponto de vista funcional / Obesity in adulthood is a risk factor for developing dementia. The populational rise in obesity and life expectancy increase the importance of search for strategies for prevention and treatment to reduce the risk of cognitive decline. In this study we evaluated if in elderly obese with Mild Cognitive Impairment, weight loss induced by diet could improve aspects of cognition, and if the apolipoprotein E genotype, metabolic profile and inflammatory markers also influence these tests. A prospective, randomized clinical trial was conducted at Ambulatório de Endocrinologia do Hospital das Clínicas da Faculdade de Medicina da USP, between 2011 and 2013, including patients 60 years or older, with a body mass index greater than or equal to 30 kg/m2, with mild cognitive impairment. They were randomized into two groups and followed by 12 months, one with conventional medical care (conventional group), another with also group meetings with nutricionists (26-28 sessions over 12 months), in order to achieve greater weight loss (intensive group). Of the 1605 volunteers were selected 80 subjects, mean age 68.1 ± 4.9 years, education 8.8 ± 4.6 years, BMI 35.5 ± 4.4kg/m2; 13 were male (16.3%), 67 (83.6%) had metabolic syndrome; 50 were physically active. The groups had similar baseline characteristics. After 12 months there was a decrease in BMI of 1.7 ± 1.8 kg/m2 (4.9% of weight), and 85% weight loss was in fat; similar between groups. There was improvement for most of the cognitive tests, without difference between groups. In the analysis of the whole group, the weight loss induced by diet was associated with improvements in memory, executive function, attention and subjective complaints, though this association was strongest under 70 years of age and in carriers of the ?4 allele of apolipoprotein E. Changes in insulin, HOMA-IR, triglycerides, C-reactive protein and leptin were associated with improvement in some cognitive tests; increased risk of worsening was associated with higher blood pressure levels (memory and global cognition), HbA1c (executive / visuospatial) and IL6 (attention and processing speed); higher adiponectin decreased risk of worsening (visual memory/verbal). There was improvement in verbal, visual and working memory associated with diet, with respect to decreased caloric intake, carbohydrates and fats, and unrelated to decreased protein intake memory. There was improvement in functional assessment in relation to gait speed and lower limb strength and improvement in quality of life associated with functional capacity, showing that the intervention did not bring damage to these areas. Intervention with caloric restriction in obese elderly, in order to promote weight loss was safe and had beneficial effects in cognition

Introdução: A deglutição resulta de um complexo mecanismo sensoriomotor, regulado pelo sistema nervoso central. Dado seu componente voluntário, nas fases antecipatória e oral, pode sofrer influências funcionais e cognitivas associadas àquelas determinadas por doenças sistêmicas que limitam a auto-regulação, percepção e controle de fatores de risco, e o desenvolvimento de estratégias compensatórias. Na doença de Alzheimer (DA) com comprometimento dos aspectos cognitivos, das atividades de vida diária e do comportamento nas fases moderada e grave da doença ocorrem os problemas de alimentação e deglutição o que traz maiores dificuldades ao cuidador. Objetivos: Traduzir e adaptar as escalas Questionário de Habilidades de Alimentação e Deglutição (QHAD) e Questionário para Avaliação da Comunicação Funcional na Afasia (QACF-A). Verificar a correlação entre os aspectos cognitivos e funcionais da deglutição e alimentação. Verificar fatores preditivos da funcionalidade da deglutição em sujeitos com doença de Alzheimer moderada e grave. Método: Neste estudo transversal e randomizado foram incluídos 50 idosos portadores de DA de ambos os sexos, com escolaridade e idades variadas, em fases moderada e grave, e seus 50 cuidadores. Foi feita avaliação dos aspectos cognitivos em que foi aplicado com o paciente o Mini- Exame do Estado Mental (MEEM). Em avaliação funcional foi aplicado com o cuidador o Índice das Atividades de Vida Diária (AVD), o Questionário para Avaliação da Comunicação Funcional na Afasia (QACF-A). A funcionalidade da deglutição foi graduada pela Escala de gravidade da deglutição (EGD). A avaliação das dificuldades de alimentação e deglutição foi feita a partir do Questionário de Habilidades de Alimentação e Deglutição (QHAD). Resultados: A escala QHAD mostrou boa consistência enquanto o QACF-A apresentou ótima confiabilidade em todos os domínios (AC > 0,9). Foi encontrada correlação entre o domínio Situação de alimentação e habilidades (QHAD) com todos os domínios do QACF-A. A maioria dos domínios do QHAD e todos do QACF-A mostraram correlação com o MEEM, AVD e EGD. O domínio Situação de alimentação e habilidades no QHAD foi o de maior representatividade em regressão linear com o MEEM, AVD e EGD (r >0,6). Quanto o QACF-A, o domínio Realização de pedidos rotineiros foi o de maior representatividade com o MEEM e AVD (r > 0,8). Na fase moderada da DA, Estado mental e comportamento e Itens relativos à comida, bebida e deglutição (QHAD) foram os domínios que apresentaram correlação significativa com a EGD (r >0,5). Na fase grave, a Situação de alimentação e habilidades (QHAD) mostrou correlação com todos os domínios do QACF-A (r > 0,6) e também com o AVD (r=0,601) e EGD (r=0,592). Também na fase grave da DA, todos os domínios do QACF-A apresentaram correlação com o MEEM, AVD e EGD (r > 0,6). Os domínios de maior representatividade juntos aos aspectos cognitivos e funcionais foram Situação de alimentação e habilidades (QHAD) e Realização de pedidos rotineiros (QACF-A). Conclusão: Dada as alterações funcionais inexoráveis no curso da doença, é imprescindível a sua observação em pacientes com prejuízos na alimentação e nos mecanismos da deglutição. O presente estudo fornece instrumentos de avaliação para orientar cuidadores e profissionais quanto à alimentação e deglutição de pacientes com doença de DA em fases avançadas. / Introduction: Swallowing results from a complex sensory-motor mechanism regulated by central nervous system. Given the voluntary component, in anticipatory and oral phases, it can suffer functional and cognitive influences associated to those determined by systemic diseases that limit self-regulation, perception and control of risk factors and development of compensating strategies. In moderate and severe phases of Alzheimer disease (AD), with cognitive, functional daily-living and behavioral aspects compromised feeding and swallowing problems create greater difficulties for the caregiver. Objectives: to translate and adapt the scales of Assessment of Feeding and Swallowing Difficulties in Dementia (AFSDD) e Functional Outcome Questionnaire for Aphasia (FOQ-A). To verify the correlation between cognitive and functional aspects of feeding and swallowing. To verify predictive factors of swallowing functionality in patients with moderate and severe AD. Method: In this randomised and transversal study 50 elderly diagnosed with moderate and severe AD, according to Clinical Dementia Rating (CDR), of both genders, varied ages and schooling and 50 caregivers were included. The Mini-Mental Estate Examination (MMSE) was applied to evaluate cognitive conditions of the patients. The Activities of Daily Living (ADL) Index and the Functional Outcome Questionnaire for Aphasia (FOQ-A), were applied to the caregiver for patient functional evaluation. Swallowing functionality was graded by the Swallowing Rating Scale American Speech-Language-Hearing Association ASHA. The evaluation of feeding and swallowing difficulties was done by the Assessment of feeding and swallowing difficulties in dementia (AFSDD). Results: Analysis of AFSDD verified good internal consistency in most of the domains, while the FOQ-A presented excellent internal consistency in all domains (AC>0.9). There was a correlation between most of AFSDD and FOQ-A with MMSE and ADL. The domain of Feeding situation and skills in AFSDD was the most representative in linear regression, considering the MMSE, ADL and ASHA (r>0.6). Considering the FOQ-A the domain of Making routine requests was the most representative with the MMSE and ADL (r>0.8). In moderate phase of AD, Mental estate and behavior and Issues related to food, drink, and swallowing (AFSDD) were the domains that had significant correlation with ASHA (r> 0,5). In severe phase, the Feeding situation and skills (AFSDD) showed correlation with all domains of FOQ-A (r>0,6), and with ADL (r=0,601) e ASHA (r=0,592). In severe phase was observed that all domains of FOQ-A had correlation with MMSE, ADL and ASHA (r>0,6). The domains with greater representation in the cognitive and functional aspects were Feeding situation and skills (AFSDD) and Making Routing Requests (FOQ-A). Conclusion: Given the inexorable functional alterations of the disease, observing the feeding and swallowing compromises of the patients is indispensable. This study discloses instruments to evaluate and orient caregivers and other professionals regarding feeding and swallowing in patients in advanced phases of AD.

Introdução: Na Doença de Alzheimer, o comprometimento no desempenho nas Atividades de Vida Diária (AVD) impacta diretamente a autonomia e independência do indivíduo. A capacidade funcional determina o nível de auxílio que uma pessoa irá necessitar no cotidiano para uma vida em segurança e com autonomia. Dentre os domínios cognitivos, a Função Executiva tem sido relatada como a mais associada com o desempenho de funcionalidade. Há a necessidade de instrumentos válidos para avaliar os déficits das funções executivas no desempenho de tarefas de mundo real em pacientes com doença de Alzheimer (DA) no Brasil. Objetivo: Validar a versão brasileira do teste Executive Performance Test (EFPT) em pacientes com doença de Alzheimer (DA). Métodos: Adaptação cultural do EFPT para o português do Brasil. Os estudos de confiabilidade e validade foram realizados com três grupos de idosos: controles, DA leve e DA moderada. Este estudo examinou a estabilidade do instrumento, a consistência interna (alfa de Cronbach), a validade de constructo e de critério e análises de precisão. Resultados: A amostra foi composta de 83 participantes com 60 anos ou mais, distribuídos em três grupos: controle, DA leve e DA moderada. A confiabilidade inter examinadores foi alta (ICC = 0,985), com alta consistência interna (Cronbach ? = 0,967). Houve forte correlação entre EFPT-Br Total e DAFS-BR (r = -0.762), correlação fraca a moderada com a bateria cognitiva e correlação moderada a forte com a bateria funcional. Foi realizado o cálculo da da ROC multiclasse área sob a curva de 0,8933, a pontuação sugerida para diferenciar os grupos : menor que 8 para controles; entre 9 e 27 para DA leve; e acima de 28 para DA moderada, para discriminar grupos. Conclusão: O EFPT-BR é um teste válido, com parâmetros psicométricos satisfatórios, para discriminar pacientes saudáveis, com DA leve e DA moderada na realização de tarefas instrumentais. O teste fornece informações consistentes para auxiliar a compreensão do desempenho de pacientes com DA na realização de atividades de vida diária com mais autonomia e segurança / Background: In Alzheimer\'s disease, the impairment in performing Activities of Daily Life (ADL) directly affects the autonomy and independence of the individual. The functionality determine a person needs for a safe and autonomous life. Among the cognitive domains, Executive Function has been reported as the most associated with functionality performance. There is a need for valid assessments to evaluate the deficits of executive functions in performing of real world tasks with patients with Alzheimer\'s disease (AD) in Brazil. Objective: To validate to Brazilian Portuguese version of the Executive Function Performance Test (EFPT) in Alzheimer disease (AD) patients. Methods: Cultural adaptation of EFPT to Brazilian Portuguese. The reliability and validity studies were performed with three groups of elderly: controls, mild AD and moderate AD. This study examines instrument stability, an internal consistency (Cronbach\'s alpha), a construct and criterion validity, and precision analyzes. Results: The sample consisted of 83 participants aged 60 years and over, divided into three groups: control, mild AD and moderate AD. The inter-examiner reliability was high (ICC = 0.985), with high internal consistency (Cronbach ? = 0.967). There was a strong correlation between EFPT-Br Total and DAFS-BR (r = -0.762), weak to moderate correlation with a cognitive battery and moderate to strong correlation with the functional battery. We performed the calculation of the ROC multiclass area under the curve of 0.8933, a score suggested to differentiate the groups: less than 8 for controls; between 9 and 27 for mild AD; and above 28 for moderate AD, to discriminate groups. Conclusion: EFPT-BR is a valid test with satisfactory psychometric parameters to discriminate healthy patients with mild AD and moderate AD in performing instrumental tasks. The test provides consistent information to assist in understanding the performance of AD patients in carrying out more autonomous and safe daily life activities

INTRODUÇÃO: Os fatores de risco cardiovascular (FRCV) afetam o fluxo sanguíneo cerebral, contribuindo possivelmente para o declínio cognitivo e a emergência da Doença de Alzheimer (DA), a forma mais comum de demência. A tomografia por emissão de pósitrons (positron emission tomography, PET) com fluordesoxiglucose F18 (18F-FDG) é largamente usada para demonstrar o padrão específico de metabolismo cerebral de glicose reduzido em sujeitos com DA e em indivíduos não-demenciados portadores do alelo e4 da apolipoproteína E (APOE e4), o maior fator de risco genético para DA. Entretanto, estudos de PET investigando o impacto dos FRCV no metabolismo cerebral são escassos. OBJETIVO: Examinar se níveis diferentes de FRCV estariam associados com reduções na taxa de metabolismo cerebral de glicose (TMCG), envolvendo as regiões cerebrais afetadas nos estágios iniciais da DA (pré-cúneo e giro do cíngulo posterior, neocórtex parieto-temporal lateral e região hipocampal). MÉTODOS: Nós avaliamos 59 indivíduos cognitivamente preservados (66-75 anos) subdivididos em três grupos de acordo com seu escore para Framingham Coronary Heart Disease Risk (FCHDR) (alto-risco, médio-risco e baixo-risco) para os exames de ressonância magnética (RM) e de PET-FDG. Dados de PET foram corrigidos para os efeitos de volume parcial a fim de evitar efeitos confundidores devido à atrofia cerebral regional. Nós realizamos uma análise de covariância global (ANCOVA) para investigar as reduções de TMCG em associação com os três grupos, comparações entre dois grupos para as diferenças de TMCG pelo teste-t, e índices de correlação linear voxel-a-voxel entre os valores de TMCG e escores FCHDR. Todas as análises incluíram a presença ou a ausência do APOE e4 como covariada confundidora de interesse. RESULTADOS: A investigação ANCOVA de diferenças de TMCG entre os três grupos mostraram significantes diferenças de TMCG somente no giro parahipocampal direito (p=0,032). Nas comparações entre dois grupos, reduções de TMCG significantes foram detectadas no grupo de altorisco comparado ao baixo-risco no pré-cúneo esquerdo (p=0,008) e o giro do cíngulo posterior esquerdo (p=0,007). Focos inesperados de reduções de TMCG no grupo baixo-risco comparado ao grupo alto-risco no giro parahipocampal foram detectados em ambos os hemisférios direito (p=0,001) e esquerdo (p=0,045). Havia também uma significante correlação linear positiva entre valores de TMCG e escores FCHDR no giro parahipocampal em ambos os lados direito (p=0,007) e esquerdo (p=0,025). CONCLUSÃO: Depois de controlar para a presença do APOE 4, nossos achados de hipofunção cerebral regional relacionado a FRCV mantiveram a significância estatística no pré-cúneo e no giro do cíngulo posterior, as duas regiões cerebrais onde comprometimentos funcionais são os mais consistentemente detectados nos estágios incipientes da DA. Isso sugere que os achados de hipometabolismo cerebral similares àqueles vistos nos sujeitos com DA podem ser vistos em associação com a gravidade de FRCV em amostras de indivíduos cognitivamente preservados. Uma possível explicação para o hipermetabolismo relativo no giro parahipocampal nos indivíduos com elevados FRCV seria um viés na seleção da amostra. É possível que nós tenhamos excluídos os sujeitos com os níveis mais graves de risco cardiovascular que teriam exibido os padrões de reduções de TMCG no giro parahipocampal, forçando a seleção de indivíduos que estão para o alto risco cardiovascular, mas que são capazes de exibir mecanismos compensatórios para manter o funcionamento metabólico adequado para as regiões temporolímbicas, as quais são vulneráveis às mudanças microvasculares / INTRODUCTION: Cardiovascular risk factors (CVRF) are known to affect cerebral blood flow, possibly contributing to cognitive decline and to the emergence of Alzheimers disease (AD), the commonest form of dementia. Positron emission tomography (PET) with 18-fluoro-2-deoxyglucose (18FFDG) has been widely used to demonstrate specific patterns of reduced brain glucose metabolism in AD subjects and in non-demented individuals carriers of the apolipoprotein e4 allele (APOE e4), the major genetic risk factor for DA. However, PET studies investigating the impact of CVRF on cerebral metabolism have been scarce to date. OBJECTIVE: To examine whether different levels of CVRF would be associated with cerebral metabolic rate of glucose (CMRgl) reductions, involving brain regions affected in early stages of DA (precuneus and posterior cingulate gyrus, lateral temporalparietal neocortices and hippocampal region). METHODS: We assessed 59 cognitively preserved individuals (66-75 years), subdivided into three groups according to their Framingham Coronary Heart Disease Risk (FCHDR) score (high-risk, medium-risk, and low-risk), both with magnetic resonance imaging (MRI) and FDG-PET scans. PET data were corrected for partial volume effects to avoid confounding effects due to regional brain atrophy. We performed an overall analysis of covariance (ANCOVA) to investigate CMRgl reductions in association with the three groups, two-group comparisons of CMRgl differences by t-tests, and voxelwise linear correlation indices between CMRgl values and FCHDR scores. All analysis included the presence or absence of the APOE 4 allele as a confounding covariate of interest. RESULTS: The ANCOVA investigation of CMRgl differences across the three groups showed significant CMRgl differences only in the right parahippocampal gyrus (p=0.032). In the two-group comparisons, significant CMRgl reductions were detected in the high-risk group compared to the lowrisk group in the left precuneus (p=0.008); and the left posterior cingulate gyrus (p=0.007). Unexpected foci of CMRgl reductions in the low-risk compared to the high-risk group in the parahippocampal gyrus were detected, both on the right (p=0.001) and left (p=0.045) hemispheres. There was also a significant positive linear correlation between CMRgl values and FCHDR scores in the parahippocampal gyrus both for the right (p=0.007) and left (p=0.025) sides. CONCLUSION: After controlling for the presence of the APOE 4 allele, our findings of CVRF-related regional brain hypofunction retained statistical significance in the precuneus and posterior cingulate gyrus, the two brain regions where functional impairments are most consistently detected in incipient stages of AD. This suggests that findings of brain hypometabolism similar to those seen in AD subjects can be seen in association with the severity of CVRF in samples of cognitively preserved individuals. One possible explanation for the relative hypermetabolism in the parahippocampal gyrus in high CVRF individuals would be a bias in the sample selection. It is possible that we have excluded subjects with severest levels of cardiovascular risk who would have displayed patterns of reduced CMRgl in the parahippocampal gyrus, forcing the selection of individuals who are at high cardiovascular risk but are capable of displaying compensatory mechanisms to maintain adequate metabolic functioning in temporolimbic regions vulnerable to microvascular changes

A literatura científica vem debatendo sobre a existência de uma associação entre diabetes mellitus (DM) e demência, doença de Alzheimer (DA) e demência vascular (DV). O DM é um conhecido fator de risco para a doença cerebrovascular (DCV) e DV, porém não há consenso até o momento do real papel do DM no desenvolvimento das alterações neuropatológicas da DA. Objetivos: verificar a associação entre DM e demência, DM e alterações neuropatológicas da DA e DV. Métodos: os dados foram coletados do Banco de Encéfalos Humanos do Grupo de Estudos em Envelhecimento Cerebral da FMUSP estudados de 2004 a 2015. A amostra foi dividida em dois grupos: não diabéticos e diabéticos. Os diagnósticos de DM e de demência foram estabelecidos post-mortem mediante entrevista com informante. O diagnóstico de demência exigiu escore >= 1 na Escala de Avaliação Clínica da Demência (CDR) e Questionário sobre Declínio Cognitivo no Idoso (IQCODE) >= 3,42. O diagnóstico etiológico da demência foi determinado por exame neuropatológico por imuno-histoquímica. A proporção de casos de demência, de DA e de DV de não diabéticos e diabéticos foi determinada, assim como a relação entre DM e placas neuríticas (PN) e emaranhados neurofibrilares (ENF), e neuropatologia vascular. As análises estatísticas empregadas foram o teste de Mann-Whitney e regressão linear múltipla para variáveis quantitativas, teste de ?2, teste exato de Fisher e regressão logística múltipla para variáveis categóricas. Resultados: amostra total foi de 1.037 indivíduos, sendo 758 não diabéticos (73,1%) e 279 diabéticos (26,9%). Demência foi constatada em 28,7% em diabéticos. O DM não se associou à frequência mais elevada de demência (OR: 1,22; IC 95%: 0,81-1,82; p=0,34). O DM não está associado com ENF (p=0,81), PN (p=0,31), grupo infarto (p=0,94), angiopatia amiloide (p=0,42) e arteriolosclerose hialina (p=0,07). Após o ajuste para variáveis demográficas e para os fatores de risco vascular, o diagnóstico de DM não se associou ao diagnóstico neuropatológico de DA e vascular. Conclusão: o DM não está associado à demência e às alterações neuropatológicas da DA e de DV / The scientific literature has been debating the existence of an association between diabetes mellitus (DM) and dementia, Alzheimer\'s disease (AD) and vascular dementia (VaD). DM is a known risk factor for cerebrovascular disease (CVD) and VaD, but there is still no consensus on the real role of DM in the development of AD neuropathology. Objectives: to investigate the association among DM and dementia, neuropathology (NP) of AD and VaD. Methods: Data were collected from the cases included in the Brain Bank of the Brazilian Aging Brain Study Group between 2004 and 2015. Cases were divided into 2 groups: no diabetics and diabetics. Clinical diagnosis of dementia was determined by the scores >= 1.0 in the Clinical Dementia Rating (CDR) and >= 3.42 in the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Etiological diagnoses of dementia were determined by neuropathological examination, using immunohistochemistry. The proportion of dementia cases, AD and VaD of no diabetics and diabetics were investigated as well as the relationship among DM and neuritic plaques (NPq) and neurofibrillary tangles (NFT). Mann-Whitney test and multiple linear regression for quantitative variables, and chi-square test and multiple logistic regression for categorical variables were the statistical analyses applied. Results: Total sample included 1037 subjects, divided in 758 (73.1%) no diabetics and 279 diabetics (26.9%). Dementia was present in 27.8% of diabetics. DM did not increase the frequency for dementia (OR: 1.22; IC 95%: 0.81-1.82; p=0.34). DM was not associated with NFT (p=0.81), NPq (p=0.31), infarct group (0.94), cerebral amyloid angiopathy (0.42) and hyaline arteriolosclerosis (p=0.07). After adjustment for demographic variables and vascular risk factors, DM was not associated with DA and vascular NP. Conclusion: DM is not associated with dementia, AD and vascular neuropathology

La dégénérescence maculaire liée à l’âge ou DMLA représente la première cause de cécité légale dans les pays industrialisés. C’est une affection multifactorielle (facteurs environnementaux et génétiques), caractérisée par la dégénérescence des photorécepteurs et une dysfonction de l’épithélium pigmentaire de la rétine (EPR). La présence de dépôts sous-rétiniens, les drusen, qui sont un facteur de risque de développer la DMLA contiennent de l’amyloïde-b (Ab), le peptide neurotoxique impliqué dans la maladie d’Alzheimer (MA) et le facteur H du complément (CFH), qui est un des inhibiteurs solubles majeurs de l’activation de la voie du complément. L’Aβ est capable de lier le CFH et il existe une corrélation inverse entre les taux de CFH et d’Aβ dans le cerveau et la rétine de modèles murins de la MA, de plus, le polymorphisme H402Y dans le gène codant pour le CFH est associé à la moitié des cas de DMLA et est aussi un facteur de risque pour la MA. Au début de ma thèse, rien n’était connu sur les fonctions de la protéine précurseur de l’amyloïde β (APP), et du CFH dans la rétine. Ainsi, le but de ma thèse a été d’étudier d’une part le rôle physiologique de l’APP au cours de la différenciation de la rétine et à l’âge adulte chez la souris, et d’autre part le CFH dans la rétine normale chez la souris normale adulte et chez la souris Rd10, un modèle de dégénérescence des photorécepteurs. Nous avons montré par l’utilisation d’une souris dont le gène de l’APP est invalidé (APPko), une diminution stable de 35% de nombre de cellules amacrines glycinergiques et de 36% de celui des cellules bipolaires, associé à une désorganisation importante des laminations des synapses au stade adulte, et une augmentation transitoire à 50% du nombre cellules horizontales au cours de la phase précoce de la différenciation rétinienne. Nous avons identifié Ptf1a, facteur de transcription indispensable à la différenciation des cellules amacrines, comme la cible de l’APP. De plus, non montrons que SorLA, le récepteur de l’APP, est indispensable à la fonction de différenciation rétinienne de l’APP. Dans la deuxième partie de mon étude, j’ai montré que le CFH protége in vitro les cellules de l’EPR contre les effets létaux du stress oxydant. Après avoir caractérisé les processus associés à la dégénérescence des photorécepteurs chez la souris Rd10 (activation gliale, microgliale, activation de l’inflammation et de la voie du complément), j’ai montré que l’injection intrapéritonéale répétée de CFH humain durant la dégénérescence protège partiellement les photorécepteurs de la mort. L’ensemble de mon étude montre pour la première fois un rôle important de l’APP dans la différenciation de la rétine et un nouveau rôle, comme antioxydant, pour le CFH, qui pourrait être un agent thérapeutique ciblant des photorécepteurs et l’EPR dans les pathologies dégénératives rétiniennes. / Age-related macular degeneration (AMD) is the first cause of central vision loss, due to photoreceptor degeneration and retinal pigmented epithelium (RPE) dysfunction. It is a multifactorial disease (genetic and environmental factors) and subretinal deposits of materials called drusen, is a major risk to develop AMD. Drusen contain amyloïd β (Aβ), the major neurotoxic peptide involved in Alzheimer disease (AD), and complement factor H (CFH), one of the major inhibitor of the complement pathway. Aβ and CFH interact and there is an inverse correlation between CFH and Aβ in the brain and retina of mouse models of AD. Polymorphism H402Y of CFH may be a cause of AMD in as many as 50% of cases. At the beginning of my thesis, nothing was known about the role of the amyloid precursor protein (APP) in the retina, as well as CFH. Therefore, the aim of my work was to investigate the retinal functions of both APP during retinal development and in adult mouse and CFH in normal mouse and in the Rd10 mouse model of photoreceptor degeneration. By using a mouse knock-out for app, we showed that APP regulates differentiation of retinal interneurons: it positively controls differentiation of glycinergic amacrine cells and bipolar cells, whereas it negatively controls differentiation of horizontal cells. Moreover, we identified the transcription factor, Ptf1-1, as a main transcriptional target of APP. Finally, we demonstrated that SorLA, an APP receptor, participates to the differentiation role of APP in the retina. In the second part of the study, I demonstrated that CFH protects RPE cells from lethal oxidative stress in cultures. Moreover, I showed that expression of CFH is very low in neural retina in comparison to the RPE/choroid/sclera complex in normal mice, and that CFH expression increases in both the neural retina and the RPE/choroid/sclera complex during photoreceptor degeneration in the Rd10 mice, suggesting an adaptive response of these tissues to degeneration. Intrapéritonéale injections of CFH partially protect photoreceptors from degeneration, suggesting a protective effect of CFH against retinal degeneration. Altogether, my study showed for the first time a physiological function of APP in the retina, and a new role for CFH in the protection of photoreceptors against degeneration, suggesting that it may be a therapeutic target against retinal degeneration.